D-0553-2023 Class II Ongoing

Recalled by Northwind Pharmaceuticals LLC — Indianapolis, IN

FDA drug recall D-0553-2023 was initiated by Northwind Pharmaceuticals LLC on Mar 16, 2023 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing. Affected quantity: a)164 bottles; b) 198 bottles.

Recall details

Product Type
Drugs
Report Date
May 3, 2023
Initiation Date
Mar 16, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a)164 bottles; b) 198 bottles

Product description

Tadalafil Tablets, USP 20 mg, packaged in a) 6-count bottles (NDC 51655-473-87), and b) 15-count bottles (NDC 51655-473-54), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.

Reason for recall

CGMP Deviations

Distribution pattern

Nationwide with the United States

Code information

a) Lot #: F113892002, Exp. Date 08/31/2023; F113892201, Exp. Date 11/30/2023 b) Lot #: F113892001, Exp. Date 08/31/2023; F113892202, Exp. Date 11/30/2023; F113892203, Exp. Date 12/31/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0553-2023
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0553-2023. Report a data issue: hello@regdatalab.com.